Delphian Pharmaceuticals

Delphian Pharmaceuticals is a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics for oncology. The company's lead program, DP-2976, is a first-in-class inhibitor of the p97 ATPase, also known as Valosin-containing protein (VCP), which plays a central role in cellular protein homeostasis. By inhibiting p97, Delphian aims to disrupt the ability of cancer cells to manage misfolded proteins, thereby inducing proteotoxic stress and apoptosis. Founded by Dr. Frank Giles, a leader in clinical oncology, the company is headquartered in Chicago and has conducted early-stage clinical trials in patients with advanced solid tumors. The company's approach targets a critical node in the ubiquitin-proteasome system, offering a potential new treatment modality for various cancers that are resistant to standard proteasome inhibitors.